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Simple Summary: We investigated the clinical significance of interim response evaluation during
definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Interim
response was evaluated using adaptive CT images including primary esophageal lesion and lymph
node. The reduction rate of tumor area or diameter was measured. Interim response correlated with
complete response and survival rates. That is, the evaluation of tumor burden reduction during
treatment may help predict patient prognosis.
Abstract: The study aimed to investigate the clinical significance of interim response evaluation
during definitive chemoradiotherapy (dCRT) in predicting overall treatment response and survival
of patients with locally advanced esophageal squamous cell carcinoma (LAESCC). We reviewed
194 consecutive patients treated with dCRT for biopsy-confirmed LAESCC. A total of 51 patients
met the inclusion criteria. Interim response was assessed by defining a region of interest in initial
and adaptive computed tomography (CT) images and subsequently examined against the overall
treatment response assessed three months after dCRT, treatment failure pattern, overall survival (OS),
and progression-free survival (PFS) estimates. Reductions in both the area and maximal diameter
of the primary lesion (p < 0.001; p < 0.001, respectively) and those of the metastatic lymph nodes
(LN) (p = 0.002; p < 0.001, respectively) in interim analysis were significantly higher among patients
who achieved complete response (CR) than among those who did not. OS was significantly longer
among patients who showed ≥30% interim reduction in the area and maximal diameter of the
primary lesion and among those who showed such reduction in both the primary lesion and LN.
PFS was significantly longer in the patients with ≥30% interim reduction in the area of the primary
lesion. In addition, the proportion of cases with locoregional failure began decreasing at interim
response of 20% or higher, while the proportion of cases with outfield failure followed the opposite
pattern, increasing at interim response of 20% or higher. Among patients treated with dCRT for
LAESCC, interim response assessed using adaptive CT images correlated with overall CR and OS
rates. The evaluation of tumor burden reduction during dCRT may help predict patient prognosis.
Keywords: esophageal cancer; definitive CRT; adaptive radiotherapy; adaptive CT; interim response
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1. Introduction
Esophageal cancer is the eighth most common cancer worldwide; it is associated with
poor prognosis, which makes it also the sixth leading cause of cancer-related deaths [1].
Squamous cell carcinoma is the most prevalent histological subtype of esophageal cancer,
while the incidence of adenocarcinoma is increasing in Western countries [2,3]. A staging
system based on tumor-node-metastasis subclassification is available. However, esophageal
cancers are often categorized according to the indicated treatments into early-stage su-
perficial cancers, locally-advanced cancers with, or without, regional lymph node (LN)
metastases in the absence of distant metastases, and cancers with distant metastases [4].
Patients with locally advanced esophageal cancer are a heterogeneous group that can be
further divided into those with potentially resectable (T2 up to T4a) and unresectable (T4b)
primary disease, poor surgical candidates, and those who decline surgery [5].
Surgery had been regarded as a standard treatment for patients with resectable
esophageal cancer. However, patient outcomes remain unsatisfactory with median survival
rarely exceeding 18 months [6]. Moreover, most patients are diagnosed when the dis-
ease has reached advanced or unresectable stages. Standard therapy for locally advanced
esophageal squamous cell carcinoma (LAESCC) includes neoadjuvant chemotherapy or
chemoradiotherapy (CRT) followed by surgery or definitive CRT (dCRT) [7]. Patients
undergoing dCRT may experience local recurrence and require salvage surgery, while
two-year survival rates have been reported as 31–40% [8–10].
Adaptive radiation therapy (ART) is a mid-treatment process where the initial radio-
therapy (RT) plan is modified to account for the anatomical changes in the tumor or organs
at risk, aiming to deliver an accurate dose of radiation to the target while minimizing
the risk of toxicity [11]. At our institution, ART consists of a second set of computed
tomography (CT) scanning simulation and RT planning, usually three to five weeks into
dCRT to accommodate anatomical changes due to tumor shrinkage. These may provide
additional information regarding early (interim) treatment response. In contrast, conven-
tional treatment response evaluation is performed one to three months after treatment
completion, based on a comparison of pre- and post-treatment radiologic studies.
The present study aimed to evaluate the role of interim response evaluation during
dCRT for LAESCC patients in predicting overall treatment response and survival rates.
The differences in treatment failure patterns based on the interim response were also
investigated.
2. Materials and Methods
2.1. Patient Identification
Patients who underwent dCRT for the treatment of locally advanced (stages II–IV)
esophageal cancer at the Gangnam Severance Hospital and Severance Hospital between
January 2005 and December 2018 were screened for eligibility. Only biopsy-confirmed
squamous cell carcinoma cases with a measurable primary esophageal lesion on a baseline
CT scan were included in the analysis. Patients were excluded from the present study if
they did not undergo a CT scanning simulation for ART during dCRT or if they underwent
esophageal stent insertion before or during dCRT. In general, patients underwent ART if
the initial CT showed the gross tumor deviating the normal anatomy of the esophagus
(usually ≥T3) and/or patients complained of symptomatic dysphagia (≥Grade 2, CTCAE
4.0) during the initial physical examination. Among 194 patients with LAEC treated with
dCRT, patients with non-squamous cell carcinoma histology, an unmeasurable primary
esophageal lesion in CT, esophageal stent insertion, and no adaptive CT images were
excluded. Patients were assessed by endoscopic ultrasonography, chest and abdominal
CT scans, and 18F-fluorodeoxyglucose positron emission tomography or positron emission
tomography-CT (PET-CT) scans. The eighth edition of the American Joint Commission on
Cancer stating system was used [4].
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2.2. Treatment Regimens
All patients underwent definitive concurrent CRT. RT was performed with three-
dimensional conformal RT or intensity-modulated RT using conventional fractionation
schedules (5 days/week, 1.8–2.0 Gy/daily fraction) and the cone-down technique at the
time of ART. Gross tumor volume means primary tumor and metastatic regional LNs
on images. Clinical target volume was determined as gross tumor volume plus 3 cm
craniocaudally, 1 cm laterally, and 3 cm into the gastric mucosa in case of gastroesophageal
junction tumors. A uniform 0.5-cm expansion from clinical target volume was added to
define planning target volume. The regimen of concurrent chemotherapy was mainly
cisplatin and 5-fluorouracil. The dose and schedule was 75 mg/m2 on day 1 for cisplatin
and 1000 mg/m2 on days 1–4 for 5-fluorouracil, every 4 weeks in most LAESCC patients.
2.3. Defining Regions of Interest and Interim Analysis at ART
Contrast-enhanced initial and adaptive CT images were loaded into the Picture Archiv-
ing and Communication System software (CentricityTM PACS, GE Healthcare, Slough,
United Kingdom) for the measurement of lesions. Initial CT scanning included diag-
nostic CT images taken at baseline and simulation CT images acquired for initial RT
planning. An experienced radiation oncologist selected axial CT slices containing the
primary esophageal lesion and the regional metastatic LNs with the largest diameters.
In these axial CT images, regions of interest (ROIs) were manually delineated along the
boundaries of tumor lesions. The area of ROI was measured including the necrotic area
within the tumor, while carefully excluding adjacent fluid or air volumes or normal esoph-
agus. The maximal diameter of esophageal cancer lesion and diameter of LN were also
measured. Changes in these measurements between initial CT and adaptive CT images
were calculated. An example of an ROI measuring is provided in Figure 1.
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was defined as tumor residue not visible on endoscopy, histologic examination, chest CT 
and PET scan. CR was decided considering all examinations of endoscopy, chest CT, and 
PET. After dCRT for esophageal tumors, a thickening of the esophageal wall can remain 
in chest CT. Thus, chest CT was used mainly to evaluate CR for LN not primary lesion. 
To evaluate the CR for primary esophageal lesion was mainly endoscopic biopsy and PET. 
Gross tumor disappearance on endoscopy, no tumor cell on biopsy, and normalization of 
tumor FDG activity on PET were defined CR for the esophageal lesion. Treatment failure 
was defined as disease recurrence after achieving CR or incomplete remission after dCRT. 
Figure 1. Measurement of region of interest (ROIs) based on initial computed tomography (CT) and adaptive CT scans.
he area and aximal diameter of the esophageal lesion in the initial CT scan was 4.79 cm2 and 1.55 cm, respectively. In the
adaptive CT scan, the corresponding values were 2.28 cm2 and 0.97 cm, respectively.
2.4. Assessment of Overall Treatment Response
The overall treatment response was assessed on endoscopy and chest CT, abdominal
pelvic CT, and PET-CT scans 3 months after the end of dCRT, following the Response
Evaluation Criteria for Solid Tumors (RECIST) version 1.1 [12]. A complete response (CR)
was defined as tumor residue not visible on endoscopy, histologic examination, chest
CT and PET scan. CR was decided considering all examinations of endoscopy, chest CT,
and PET. After dCRT for esophageal tumors, a thickening of the esophageal wall can remain
in chest CT. Thus, chest CT was used mainly to evaluate CR for LN not primary lesion.
To evaluate the CR for primary esophageal lesion was mainly endoscopic biopsy and PET.
Gross tumor disappearance on endoscopy, no tumor cell on biopsy, and normalization of
tumor FDG activity on PET were defined CR for the esophageal lesion. Treatment failure
was defined as disease recurrence after achieving CR or incomplete remission after dCRT.
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Treatment failure was sub-classified into locoregional and outfield failure. Locoregional
failure is a treatment failure in the esophagus or regional LN within the RT field, whereas
outfield failure is a treatment failure in other areas.
2.5. Statistical Analyses
The index date was day of LAESCC diagnosis. All enrolled patients were followed-up
until their last visit, death, or October 2019, whichever occurred first. The chi-square or
Fisher’s exact tests and Student t-tests were used to analyze statistical correlations between
categorical, and non-categorical variables. Overall survival (OS) was measured from the
date of diagnosis to the date of death or the date of the last follow-up visit. Progression-free
survival (PFS) was measured from the date of treatment initiation until disease progression
or worsening. OS and PFS were analyzed by the Kaplan–Meier method. Multivariate
analysis was performed by logistic regression and Cox regression model. A p-value of
<0.05 was considered significance. The IBM SPSS Statistics for Windows, Version 25.0.
(Armonk, NY, USA: IBM Corp) and SAS version 9.4 (SAS Institute, Cary, NC, USA) was
used for statistical analyses.
2.6. Ethical Considerations
The present study was performed in accordance with the Helsinki Declaration and
approved by the institutional review board of Gangnam Severance Hospital (3-2018-0338).
All data were de-identified and anonymized.
3. Results
3.1. Baseline Characteristics of Patients
Among 194 screened patients, 51 met the inclusion criteria, and their treatment data
were analyzed. Baseline characteristics of the patients are shown in Table 1. The mean
age of the patients was 65.6 ± 9.1 years, 43 (84.3%) were male, clinical stage III was the
most frequent (31, 60.8%), and most patients (45, 88.2%) received chemotherapy with the
5-fluorouracil plus cisplatin regimen. The median total radiation dose was 6300 (4200–7200)
cGy. The median follow-up duration was 16.6 (10.2–41.3) months.
Table 1. Baseline characteristics of the patients with esophageal squamous cell carcinoma receiving
definitive chemoradiotherapy.
Characteristics Values (n = 51)
Age (years, mean ± SD) 65.6 ± 9.1
Male (n, %) 43 (84.3)






Clinical T Stage (n, %)





Clinical N Stage (n, %)
N0 4 (7.8)
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Table 1. Cont.




Clinical M Stage, n (%)
M0 51 (100.0)
Clinical TNM stage (n, %)
Stage II 11 (21.6)
Stage III 31 (60.8)
Stage IVA 9 (17.6)




N/A (Uncertain invasiveness) 8 (15.7)
Chemotherapy regimen
5-FU + cisplatin 45 (88.2)
Others c 6 (11.8)
Consolidation chemotherapy (n, %) 27 (52.9)
Adaptive RT dose, cGy [median (min–max) 3570 (2300–6300)
Total dose, cGy [median (min–max)] 6300 (4200–7200)
SD, standard deviation; IQR, interquartile range; AJCC, American Joint Committee on Cancer; WD, well differ-
entiated; MD, moderately differentiated; PD, poorly differentiated; RT, radiotherapy. a Follow up duration for
survivors was 26.2 (15.8–51.2) months. b Unevaluable was due to the fact that EUS cannot be performed because
scope passing is limited. c 5-FU + carboplatin, Docetaxel + 5-FU + cisplatin, paclitaxel + carboplatin, cisplatin
monotherapy.
3.2. Interim Analysis
The mean time interval between the initial and adaptive CT scan was approximately
1 month (30.6 ± 7.3 days). The interim response evaluation revealed mean reduction of
33.7 ± 24.0% in the area and 32.0 ± 23.4% in the diameter of the primary esophageal lesion.
In the case of LN, 27.2 ± 25.1% reduction in the area and 16.6 ± 19.2% reduction in the
diameter were observed. When the interim responses of both primary tumor and LNs were
combined, the mean reductions observed were 32.4 ± 22.4% and 25.8 ± 22.6% in the area
and diameter, respectively (Table 2).
Table 2. Interim treatment response from the comparison between initial and adaptive CT images.
Interim Treatment Response Values (n = 51)
Interval between initial and adaptive CT,
days (mean ± SD) 30.6 ± 7.3
Primary esophageal lesion
Initial area (cm2), (median, IQR) 5.9 (3.8–8.6)
Follow up area (cm2), (median, IQR) 4.0 (2.3–5.6)
Initial diameter (cm), (median, IQR) 1.8 (1.4–2.7)
Follow up diameter (cm), (median, IQR) 1.3 (0.8–1.6)
Reduction of area (%, mean ± SD) 33.7 ± 24.0
Reduction of diameter (%, mean ± SD) 32.0 ± 23.4
LN
Initial area (cm2), (median, IQR) 2.5 (1.5–3.8)
Follow up area (cm2), (median, IQR) 1.7 (1.1–3.3)
Initial diameter (cm), (median, IQR) 2.1 (1.7–2.5)
Follow up diameter (cm), (median, IQR) 1.7 (1.4–2.1)
Reduction of area (%, mean ± SD) 27.2 ± 25.1
Reduction of diameter (%, mean ± SD) 16.6 ± 19.2
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Table 2. Cont.
Interim Treatment Response Values (n = 51)
Sum of primary lesion and LN
Initial area (cm2), (median, IQR) 8.2 (5.4–12.1)
Follow up area (cm2), (median, IQR) 5.7 (3.6–8.1)
Initial diameter, (median, IQR) 3.3 (2.1–4.8)
Follow up diameter, (median, IQR) 2.8 (1.3–3.6)
Reduction of area (%, mean ± SD) 32.4 ± 22.4
Reduction of diameter (%, mean ± SD) 25.8 ± 22.6
SD, standard deviation; IQR, interquartile range; LN, lymph node; CT, computed tomography.
3.3. Overall Treatment Response and Pattern of Failure
Of 51 patients, 26 (51%) showed CR 3 months after dCRT and 9 (35.6%) showed
recurrence during the follow-up period. Treatment failure, including incomplete remission
and recurrence after achieving CR, were reported in 34 (66.7%) patients. Among 34 failure
cases, 16 (47.1%) were locoregional (esophageal recurrence or periesophageal regional
LN metastasis), 12 (35.3%) were outfield failures, and 6 (17.6%) were both locoregional
and outfield failures (Figure 2). The lungs were the most common solid organ affected in
cases of outfield failure, accounting for 9 (26.5%) patients. Finally, 22 (43.1%) patients were
confirmed dead during the 13-year follow-up period.
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Figure 2. Flow chart capturing tre tment outco es according to the cli ical course. LAEC, locally advanced esophageal
cancer; CRT, chemoradiotheray; SqCC, squamous cell carcinoma.
3.4. Prognostic Significance of Interim Analysis
Factors associated with CR are shown in Table 3. Interim responses were significantly
correlated with CR. Reductions to the area and diameter of the primary esophageal lesion
in the CR group were significantly higher than those in the non-CR group (18.4% vs. 48.4%,
p < 0.001, and 16.3% vs. 47.6%, p < 0.001, respectively). The reduction of LN area and
diameter were also higher in the CR group than in the non-CR group (15.2% vs. 40.6%,
p = 0.002, and 5.8% vs. 28.7%, p < 0.001, respectively). The sum of area and that of
diameter reduction were significantly higher in the CR group than in the non-CR group
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(17.7% vs. 46.5%, p < 0.001, and 10.5% versus 40.5%, p < 0.001, respectively). However,
there was no difference in baseline stages between the CR and non-CR group.
Table 3. Factors associated with complete response (CR).
Variables Non-CR(n = 25)
CR
(n = 26) p-Value
Age (years, mean ± SD) 66.4 ± 8.0 64.9 ± 10.1 0.567
Primary esophageal lesion
Initial area (cm2), (median, IQR) 6.1 (4.1–9.0) 5.7 (2.8–8.5) 0.666
Reduction of area (%, mean ± SD) 18.4 ± 18.0 48.4 ± 19.5 <0.001
Initial diameter (cm), (median, IQR) 1.8 (1.4–2.6) 1.8 (1.2–2.7) 0.926
Reduction of diameter (%, mean ± SD) 16.3 ± 20.4 47.6 ± 14.5 <0.001
LN
LN initial area (cm2), (median, IQR) 2.5 (1.5–4.1) 2.5 (1.9–3.7) 0.769
Reduction of LN area (%, mean ± SD)) 15.2 ± 21.4 40.6 ± 22.4 0.002
LN initial diameter (cm), (median, IQR) 2.0 (1.5–2.6) 2.1 (1.8–2.6) 0.437
Reduction of LN diameter (%, mean ± SD) 5.8 ± 14.6 28.7 ± 16.5 <0.001
Sum of primary lesion and LN
Initial Area (cm2), (median, IQR) 8.6 (5.9–12.0) 6.9 (3.6–12.6) 0.254
Reduction of area, sum (%, mean ± SD)) 17.7 ± 17.1 46.5 ± 17.5 <0.001
Initial diameter (cm), (median, IQR) 3.3 (2.6–4.4) 3.3 (1.9–4.8) 0.618
Reduction of diameter, sum (%, mean ± SD) 10.5 ± 19.3 40.5 ± 14.4 <0.001
Clinical Stage (n, %)
0.145
Stage II 4 (16.0) 7 (26.9)
Stage III 14 (56.0) 17 (65.4)
Stage IVA 7 (28.0) 2 (7.7)
SD, standard deviation; IQR, interquartile range; CR, complete response; LN, lymph node. Bold value means
statistical significance because p value is < 0.05.
To determine the significance of interim response to treatment failure patterns, we an-
alyzed data from 16 (47.1%) and 12 (35.3%) patients with locoregional and outfield failures,
respectively, while excluding 6 (17.6%) patients with both locoregional and outfield failures
from the total of 34 patients who experienced treatment failure (Figure 2). There was no
difference in the reduction of primary lesion (area and diameter) between the patients with
locoregional and those with outfield failures. When the patients experiencing treatment fail-
ure were grouped by the degree of interim reduction in the area of the primary esophageal
lesion from 5% to 30% in 5%-increments, the proportion of cases with locoregional failure
began decreasing at interim response of 20% or higher (p = 0.0501), while the proportion of
cases with outfield failure followed the opposite pattern, increasing at interim response of
20% or higher (p = 0.0533) (Figure 3).
Figure 4 presents Kaplan–Meier curves for OS, depending on interim responses.
Area and diameter reduction of the primary esophageal lesion of >30% at interim assess-
ment was associated with increased OS; in contrast, the area reduction of LN was not
significantly associated with OS (area: p-value 0.001, diameter: p-value 0.005) (Figure 4a,b).
In cases where the sum of primary esophageal cancer lesion and LN decreased by more
than 30%, both area and diameter showed increased survival rate (area: p < 0.001, diameter:
p = 0.014) (Figure 4c). PFS was significantly longer in the patients with ≥30% interim
reduction in the area of the primary lesion (p-value 0.012) (Figure S1). Table 4 showed the
multivariate analyses about CR and OS. Area reduction of the primary esophageal lesion
and the sum of area reduction were significantly associated with CR and OS
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Table 4. Multivariate analyses about complete response and overall survival rates.
For Complete Response Univariable Model Multivariable Model 1 Multivariable Model 2
OR(95% CI) p-Value OR(95% CI) p-V lue OR(95% CI) p-Value
Age 1.02(0.96–1.08) 0.559
Primary esophageal lesion
Reduction of area 0.90(0.84–0.95) <0.001 0.88(0.78–0.99) 0.029
Reduction of diameter 0.91(0.87–0.96) <0.001
Lymph node (LN)
Reduction of area 0.95(0.91–0.99) 0.008 0.97(0.92–1.03) 0.304
Reduction of diameter 0.91(0.85–0.97) 0.004
Sum of primary lesion and LN
Reduction of area, sum 0.90(0.85–0.95) <0.001 0.89(0.84–0.95) <0.001
Reduction of diameter, sum 0.88(0.81–0.94) <0.001
Clinical Stage (ref: Stage II)
Stage III 1.44(0.35–5.95) 0.386 2.79(0.20–39.80) 0.962 2.42(0.38–15.25) 0.764
Stage IVA 6.12(0.83–45.02) 0.064 8.79(0.14–544.29) 0.374
9.62(0.71–
130.07) 0.118
For Overall Survival Rates Univariable Model Multivariable Model 1 Multivariable Model 2
HR(95% CI) p-Value HR(95% CI) p-Value HR(95% CI) p-Value
Age 0.99(0.94–1.03) 0.54
Primary esophageal lesion
Reduction of area 0.98(0.97–0.99) 0.001 0.98(0.96–0.99) 0.002
Reduction of diameter 0.97(0.95–0.99) <0.001
Lymph node (LN)
Reduction of LN area 0.99(0.96–1.01) 0.253
Reduction of LN diameter 0.97(0.94–1.00) 0.07
Sum of primary lesion and LN
Reduction of area, sum 0.97(0.96–0.99) <0.001 0.97(0.95–0.99) 0.001
Reduction of diameter, sum 0.97(0.96–0.99) <0.001
Clinical Stage (ref: Stage II)
Stage III 0.75(0.25–2.19) 0.594 0.58(0.19–1.79) 0.346 0.65(0.22–1.98) 0.454
Stage IVA 2.29(0.72–7.30) 0.16 1.70(0.53–5.50) 0.373 1.84(0.57–5.90) 0.308
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Figure 4. Kaplan–Meier analysis of overall survival (OS) rates shows a relationship between the reduction of lesion size
and OS (a) Area reduction of the primary esophageal lesion/lymph node (LN) and OS rates; (b) Diameter reduction of the
primary esophageal lesion/LN and OS rates; (c) Area and diameter reduction of both lesions (sum of primary esophageal
lesion and LN) and OS rates.
4. Discussion
In the resent study, using a aptive CT images, we investigated the role of interim
response in predicting survival an overall treatment response among LAESCC patients
treated with dCRT. The present study showed that a favorable interim response to dCRT
was associated with overall CR rate. The CR group showed significantly higher interim
response than did the non-CR group, while the initial lesion area and diameter esti ates
were comparable between the groups. In addition, the interim response of the primary
lesion was associated with OS estimates. A favorable interim response of the LNs tended
to be associated with longer OS. However, this association was not statistically significant.
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Previously, dysphagia [13], hoarseness, advanced clinical stage [14], and gene ex-
pression including YAP1 and Bax [15–23] have been associated with poor prognosis in
LAESCC. A multicenter study of 181 patients with esophageal cancer treated with dCRT
revealed that PET response criteria in solid tumors can help evaluate therapeutic response
and the risk of disease progression and death [24–30]. However, previous studies on early
evaluation of dCRT response are rare. In addition, sometimes, it is difficult to evaluate
the SUV value of the regional lymph node differentiated from the primary esophageal
lesion. The present study has shown the benefits of an interim response evaluation in
prognostication after dCRT. Adaptive CT can give the information about tumor burden,
both primary esophageal lesion and LN. The use of adaptive CT scanning for interim
analysis is both feasible and cost-effective, since ART is part of routine RT protocol at many
institutions, helping to deliver accurate and precise dCRT doses [11].
According to multivariate analysis, the response of the primary cancer lesion showed
the best correlation with CR and OS estimates. One of the strengths of this study is
the investigation of the primary lesion response to treatment. Rather than being a two-
dimensional lesion, primary esophageal cancer is a column-shaped, three-dimensional
lesion that is challenging to measure and quantify. As a result, treatment response is
difficult to assess based on the RECIST criteria, which are otherwise widely used in the
evaluation of solid tumors. In the present study, we measured both tumor area and
maximum diameter in axial CT images, which allowed us to capture changes to the tumor
burden. We emphasized the evaluation of changes to the primary esophageal tumor burden
that emerged during dCRT and found a relationship between these changes and the overall
treatment response and prognosis.
In the present study, the degree of interim response of the primary esophageal lesion
was associated with the type of treatment failure. Specifically, we have demonstrated that
the interim primary lesion area reduction during dCRT of >15% corresponded to a higher
proportion of cases with outfield treatment failure; meanwhile, the interim reduction of
<15 corresponded to a higher proportion of cases with locoregional failure. This information
may be helpful to choose treatment strategies such as intensive local treatment or systemic
treatment. A large scale study with a long follow-up period may be required to show a
significant correlation between the interim response and treatment failure patterns, helping
physicians decide treatment strategy.
The present study has some limitations. First, this was a retrospective study, involving
a relatively small number of patients. Second, only patients with adaptive CT images taken
during dCRT were enrolled; as a result, the study may have been subject to selection bias,
as patients with a large tumor are likely to undergo ART during dCRT. Third, the dose
range for adaptive RT in the current study is quite large and a higher RT dose at adaptive
CT scan is likely to be associated with increased response at the interim analysis. During the
time period when the current study cohort underwent dCRT, patients underwent adaptive
CT scans based on the initial tumor size (i.e., earlier adaptive CT scans for larger gross
tumors) and symptomatic changes (i.e., improvement in swallowing difficulty). Based
on the current study results, we now carry out adaptive CT scans at regular intervals of
30.6~41.4 Gy. Lastly, while ROIs were compared at the same level of axial CT image, it is
difficult to confirm that the measured areas represented the entire tumor burden at the time
of image acquisition. Despite these limitations, this study presents novel evidence of the
predictive role of adaptive CT images, which may inform treatment strategies, including
dose escalation during dCRT.
5. Conclusions
Interim response evaluation using adaptive CT images during dCRT may provide
information regarding treatment response and prognosis among patients with LAESCC.
Further studies using qualitative evaluation of ROIs, such as texture analysis in a larger
population are warranted.
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